...

CCO Independent Conference Coverage


conference image

2009 Interscience Conference on Antimicrobial Agents and Chemotherapy*

September 12-15, 2009 | San Francisco, California

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.


Mouse over track for more info

Expert Highlights

These audio files are in mp3 format. To listen to the audio, simply click "Download Audio." You must be logged on to the clinicaloptions.com site to listen to or download the mp3 files.

Eric S. Daar, MD headshot Eric S. Daar, MD, discusses several reports from ICAAC 2009 on HIV-1 testing and treatment strategies. (9 minutes) Download Audio
Sally Hodder, MD headshot Sally Hodder, MD, discusses results of the substudies of the GRACE study, an important treatment trial looking at sex and race subpopulations of treatment-experienced patients. (5 minutes) Download Audio

Disclosures – Audio Expert Highlights

Eric S. Daar, MD, has disclosed that he has received grants for research support from Abbott Laboratories, Gilead Sciences, GlaxoSmithKline, Merck, and Pfizer and has served as a consultant/advisor for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Schering-Plough, and Tibotec.

Sally Hodder, MD, has disclosed that she has received grants for research support form Tibotec and Gilead Sciences and that she serves on advisory boards for Bristol-Myers Squibb, Gilead Sciences, and Tibotec. Her spouse is a former employee of Merck and owns stock in that company.

Jointly sponsored by USF Health and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Capsule Summary:

Immediate Antiretroviral Therapy Initiation in Patients With HIV-Associated Tuberculosis Does Not Decrease Morbidity and Mortality But Does Increase Incidence of Severe AEs

Patients who received immediate antiretroviral therapy demonstrated significantly shorter median time to HIV-1 RNA suppression and a significantly greater increase in CD4+ cell count at 2 months posttreatment relative to patients who received delayed treatment, but the CD4+ cell count increase difference did not persist at 12 months posttreatment.

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES